Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Menopausal Med. 2016 Dec;22(3):174-179. English. Original Article. https://doi.org/10.6118/jmm.2016.22.3.174
Cho YH , Um MJ , Kim SJ , Kim SA , Jung H .
Department of Obstetrics and Gynecology, Cheomdan Hospital, Gwangju, Korea.
Department of Obstetrics and Gynecology, Chosun University Hospital, Gwangju, Korea. bimilo@hanmail.net
Department of Obstetrics and Gynecology, Chosun University School of Medicine, Gwangju, Korea.
Abstract

OBJECTIVES: To evaluate the efficacy of raloxifene in preventing bone loss associated with long term gonadotropin-releasing hormone agonist (GnRH-a) administration. METHODS: Twenty-two premenopausal women with severe endometriosis were treated with leuprolide acetate depot at a dosage of 3.75 mg/4 weeks, for 48 weeks. Bone mineral density (BMD) was evaluated at admission, and after 12 treatment cycles. RESULTS: At cycle 12 of GnRH-a plus raloxifene treatment, lumbar spine, trochanter femoral neck, and Ward's BMD differed from before the treatment. A year after treatment, the lumbar spine and trochanter decreased slightly, but were not significantly different. CONCLUSIONS: Our study shows that the administration of GnRH-a plus raloxifene in pre-menopausal women with severe endometriosis, is an effective long-term treatment to prevent bone loss.

Copyright © 2019. Korean Association of Medical Journal Editors.